Critical Analysis: Nexentis Technologies (NASDAQ:NXTS) versus Pfizer (NYSE:PFE)

Nexentis Technologies (NASDAQ:NXTS) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Nexentis Technologies and Pfizer”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210,000.00	4.42	-$4.00 million	($96.07)	-0.01
Pfizer	$62.58 billion	2.68	$7.77 billion	$0.76	38.75

Pfizer has higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nexentis Technologies has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Profitability

This table compares Nexentis Technologies and Pfizer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-304.79%	-178.91%
Pfizer	6.80%	19.63%	8.46%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nexentis Technologies and Pfizer, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1	0	0	0	1.00
Pfizer	2	14	5	0	2.14

Pfizer has a consensus target price of $28.72, suggesting a potential downside of 2.47%. Given Pfizer’s stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Nexentis Technologies.

Institutional & Insider Ownership

61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Pfizer beats Nexentis Technologies on 11 of the 14 factors compared between the two stocks.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.